Advances in calcium blocker therapy

David R. Larach, Robert Zelis

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Calcium blockers are drugs that interfere with the entry of calcium ions into cells of a variety of tissues. Three calcium blockers, verapamil, nifedipine, and diltiazem, are currently approved for clinical use in the United States and many others are undergoing clinical trials. All calcium blockers share the effect of dilating blood vessels, although some agents are selective dilators of certain vascular beds, such as the coronary or cerebral circulation. There exist major differences among these drugs in their ability to depress myocardial contraction and inhibit cardiac impulse conduction, as well as other properties. The therapeutic actions of the agents in use, as well as the actions of the investigational calcium blockers, have been reviewed. Although calcium blockers are generally well tolerated and have fewer side effects than many alternative drugs, serious adverse effects are possible in certain clinical settings. The clinical indications for these drugs continue to expand and will likely find many uses in surgical patients, especially in the areas of cardiac surgery, neurosurgery, vascular surgery, and general surgery.

Original languageEnglish (US)
Pages (from-to)527-537
Number of pages11
JournalThe American Journal of Surgery
Volume151
Issue number4
DOIs
StatePublished - Jan 1 1986

Fingerprint

Calcium
Blood Vessels
Pharmaceutical Preparations
Cerebrovascular Circulation
Therapeutics
Myocardial Contraction
Coronary Circulation
Diltiazem
Neurosurgery
Nifedipine
Verapamil
Thoracic Surgery
Clinical Trials
Ions

All Science Journal Classification (ASJC) codes

  • Surgery

Cite this

Larach, David R. ; Zelis, Robert. / Advances in calcium blocker therapy. In: The American Journal of Surgery. 1986 ; Vol. 151, No. 4. pp. 527-537.
@article{7b3392288ff544f587cf9ca509753fea,
title = "Advances in calcium blocker therapy",
abstract = "Calcium blockers are drugs that interfere with the entry of calcium ions into cells of a variety of tissues. Three calcium blockers, verapamil, nifedipine, and diltiazem, are currently approved for clinical use in the United States and many others are undergoing clinical trials. All calcium blockers share the effect of dilating blood vessels, although some agents are selective dilators of certain vascular beds, such as the coronary or cerebral circulation. There exist major differences among these drugs in their ability to depress myocardial contraction and inhibit cardiac impulse conduction, as well as other properties. The therapeutic actions of the agents in use, as well as the actions of the investigational calcium blockers, have been reviewed. Although calcium blockers are generally well tolerated and have fewer side effects than many alternative drugs, serious adverse effects are possible in certain clinical settings. The clinical indications for these drugs continue to expand and will likely find many uses in surgical patients, especially in the areas of cardiac surgery, neurosurgery, vascular surgery, and general surgery.",
author = "Larach, {David R.} and Robert Zelis",
year = "1986",
month = "1",
day = "1",
doi = "10.1016/0002-9610(86)90119-4",
language = "English (US)",
volume = "151",
pages = "527--537",
journal = "American Journal of Surgery",
issn = "0002-9610",
publisher = "Elsevier Inc.",
number = "4",

}

Advances in calcium blocker therapy. / Larach, David R.; Zelis, Robert.

In: The American Journal of Surgery, Vol. 151, No. 4, 01.01.1986, p. 527-537.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Advances in calcium blocker therapy

AU - Larach, David R.

AU - Zelis, Robert

PY - 1986/1/1

Y1 - 1986/1/1

N2 - Calcium blockers are drugs that interfere with the entry of calcium ions into cells of a variety of tissues. Three calcium blockers, verapamil, nifedipine, and diltiazem, are currently approved for clinical use in the United States and many others are undergoing clinical trials. All calcium blockers share the effect of dilating blood vessels, although some agents are selective dilators of certain vascular beds, such as the coronary or cerebral circulation. There exist major differences among these drugs in their ability to depress myocardial contraction and inhibit cardiac impulse conduction, as well as other properties. The therapeutic actions of the agents in use, as well as the actions of the investigational calcium blockers, have been reviewed. Although calcium blockers are generally well tolerated and have fewer side effects than many alternative drugs, serious adverse effects are possible in certain clinical settings. The clinical indications for these drugs continue to expand and will likely find many uses in surgical patients, especially in the areas of cardiac surgery, neurosurgery, vascular surgery, and general surgery.

AB - Calcium blockers are drugs that interfere with the entry of calcium ions into cells of a variety of tissues. Three calcium blockers, verapamil, nifedipine, and diltiazem, are currently approved for clinical use in the United States and many others are undergoing clinical trials. All calcium blockers share the effect of dilating blood vessels, although some agents are selective dilators of certain vascular beds, such as the coronary or cerebral circulation. There exist major differences among these drugs in their ability to depress myocardial contraction and inhibit cardiac impulse conduction, as well as other properties. The therapeutic actions of the agents in use, as well as the actions of the investigational calcium blockers, have been reviewed. Although calcium blockers are generally well tolerated and have fewer side effects than many alternative drugs, serious adverse effects are possible in certain clinical settings. The clinical indications for these drugs continue to expand and will likely find many uses in surgical patients, especially in the areas of cardiac surgery, neurosurgery, vascular surgery, and general surgery.

UR - http://www.scopus.com/inward/record.url?scp=0022550080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022550080&partnerID=8YFLogxK

U2 - 10.1016/0002-9610(86)90119-4

DO - 10.1016/0002-9610(86)90119-4

M3 - Article

C2 - 3515982

AN - SCOPUS:0022550080

VL - 151

SP - 527

EP - 537

JO - American Journal of Surgery

JF - American Journal of Surgery

SN - 0002-9610

IS - 4

ER -